Sinovac partnership starts clinical trial of Omicron-specific inactivated vaccine for booster use

(Reuters illustration filepix by Dado Ruvic)

(Reuters illustration filepix by Dado Ruvic)

-A +A

KUALA LUMPUR (July 5): A kick off ceremony was held at Gleneagles Hospital Hong Kong (Gleneagles or GHK) for initiating a clinical trial to assess the safety and immunogenicity of the Sinovac’s Omicron-specific Covid-19 inactivated vaccine used as a booster shot in healthy adults, in anticipation of providing scientific evidence for future immunisation strategy.

This study is led by a medical research team of the University of Hong Kong Clinical Trials Centre (HKU-CTC) in collaboration with Gleneagles, according to a statement.

“Currently, Omicron continuously sweeps the world. I hope the clinical trial could strengthen and effectively promote vaccine research and vaccination administration,” said Professor Ivan Hung Fan-ngai, Ru Chien & Helen Lieh Professor in Health Sciences Pedagogy, Clinical Professor and Chief of Infectious Diseases, and Assistant Dean of Department of Medicine, School of Clinical Medicine, Assistant Dean (Admissions), LKS Faculty of Medicine, the University of Hong Kong (HKUMed).

Meanwhile, Cheryl Law, International Business Development Director of Sinovac, said: “It is of great significance to cooperate with Professor Hung, HKU-CTC and Gleneagles to carry out the clinical trial of the Covid-19 inactivated vaccine as a booster shot against the Omicron strain.

Follow our Covid-19 vaccination tracker to see where we are in the race to herd immunity.  

“We hope to find a solution for Hong Kong and the globe to fight against the new viruses with the results of this trial.”

Sinovac obtained a sample of the Omicron variant in early December 2021 and then actively promoted research and development of its inactivated Covid-19 vaccine (Omicron specific strain). Preclinical research demonstrated that the vaccine is safe and effective in animals.

The Omicron strain booster immunisation clinical trial was then approved by the HKU GHK Institutional Review Board (IRB) on April 12, and by the Pharmacy and Poisons Board of Hong Kong on April 14, allowing the clinical study on boosting the immunity of people against the new coronavirus strain in Hong Kong to be carried out.

In this study, a total of 300 healthy adult volunteers aged 18 and above who have been vaccinated with two or three doses of inactivated or mRNA Covid-19 vaccine will be recruited.

Sinovac Biotech Ltd is a China-based leading biopharmaceutical company that focuses on the research, innovation, manufacture, and commercialisation of vaccines that protect against human infectious diseases.

More details at www.sinovac.com.